Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

s positive airway pressure (nCPAP) intended to treat premature infants at risk for respiratory failure. Premature infants at risk for Respiratory Distress Syndrome (RDS) benefit from both nCPAP and intratracheal instillation of lung surfactants. Administration of aerosolized lung surfactants via nCPAP, may avoid the need for endotracheal intubation. The potential utility of a less-invasive method of delivering lung surfactants to treat premature infants suffering from an array of respiratory disorders has been recognized by the neonatal medical community.

Chrysalis Technologies Aerosol Generation Technology

The Chrysalis Technologies aerosol generation technology is designed to produce high-quality, low velocity aerosols for possible deep lung aerosol delivery. Aerosols are created by pumping the drug formulation through a small, heated capillary, yielding a dense aerosol with a defined particle size. The defined particle size can be readily controlled and adjusted through device modifications. Discovery has a strategic alliance with Chrysalis Technologies (a division of Philip Morris USA) to develop and commercialize aerosolized SRT to address a broad range of serious respiratory conditions. Through this alliance, Discovery gained exclusive rights to Chrysalis' novel aerosol generating technology for use with pulmonary surfactants for all respiratory diseases.

About Discovery Labs

Discovery Laboratories, Inc. is a biotechnology company developing Surfactant Replacement Therapies (SRT) for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery's technology produces a precision-engineered surfactant that is designed to closely mimic the essential properties of natural human lung surfactant. Discovery believes that its proprietary SRT pipeline has the potential to advance respiratory medicine and address a variety of respiratory diseases affecting neonatal, pediatric and adult patien
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:11/21/2014)... Nov. 21, 2014 Clementia ... Medicines Agency (EMA) has granted Orphan Medicinal ... product candidate, for the treatment of fibrodysplasia ... severely disabling genetic disease characterized by painful, ... and new abnormal bone formation. This process, ...
(Date:11/21/2014)... IRVINE, Calif. , Nov. 20, 2014  Edwards ... leader in the science of heart valves and hemodynamic ... corporate giving in 2014 to support a strong launch ... Heartbeat Matters , and to improve the global communities ... In 2014, Edwards, global corporate giving will exceed $8 ...
(Date:11/21/2014)... /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) announced today ... be presenting at the 26 th Annual Piper Jaffray ... New York . The formal presentation is scheduled ... addition, Mr. Krakauer and Jorgen B. Hansen , President ... the day. An audio webcast will be ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2
(Date:11/22/2014)... Dallas, TX (PRWEB) November 22, 2014 ... Society (ICS) as the complaint that the individual ... times for voiding. The report “Nocturia – Pipeline ... therapeutic development for Nocturia, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
(Date:11/22/2014)... York, New York (PRWEB) November 22, 2014 ... of power morcellators ( http://www.morcellatorlawsuit2015.com ) in minimally-invasive ... 450 new signatures since the end of October, Bernstein ... had signed the petition as of November 21st, 2014. ... 31st, when 86,042 supporters had signed on to the ...
(Date:11/22/2014)... wide variety and complexity of foods served at holiday ... allergies, an expert warns. "Every person is different ... that it can be really difficult to avoid all ... allergy and clinical immunology at Wake Forest Baptist Medical ... you know you have food allergies, caution should overrule ...
(Date:11/22/2014)... York, New York (PRWEB) November 22, 2014 ... filed on behalf of patients who allegedly developed Type ... forward in the federal multidistrict litigation now underway in ... LLP reports. According to court documents, the litigation will ... 10:00 a.m. The Court has directed Lead Counsel for ...
(Date:11/22/2014)... Hastings and Hastings, a discount accident attorney in ... with the option of leaving an online review using ... and easy to navigate website that has recently been ... allows clients to research the Hastings and Hastings law ... when retaining an attorney. Those who have been injured ...
Breaking Medicine News(10 mins):Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3
... treatment for women that cuts off blood flow to ... appropriate treatment for women in a Clinical Therapeutics article ... England Journal of Medicine . "UFE (also called ... and minimally invasive option for women to consider. This ...
... , SAN FRANCISCO, Aug. 13 Nile Therapeutics, ... of novel therapeutics for heart failure patients, today announced its second quarter ... , , For the second quarter of 2009, ... share, compared to a net loss of approximately $3.8 million, or $0.16 ...
... , , DENVER, Aug. ... BDMS ) , operators of PERFECT TEETH ... and six months ended June 30, 2009. For the quarter ended ... 2.0%, to $15.2 million. Net revenue increased $93,000, or 1.1%, to ...
... areas of the brain needed to perceive feelings, study ... drinking can affect the ability to recognize other people,s ... used functional MRI to monitor brain activity in 15 ... faces with positive or negative emotional expressions. The brain ...
... , GUANGZHOU, China, Aug. 13 ... Medicine" or "the Company"), a developer,and a leading distributor ... (TCM), nutritional and dietary supplements, and,medical devices and medical ... Second Quarter 2009 Highlights:, ...
... , New England Journal of Medicine Highlights ... Decrease Hysterectomy Rate in United States , , ... invasive interventional radiology treatment for women that cuts off blood flow ... treatment for women in a Clinical Therapeutics article in the Aug. ...
Cached Medicine News:Health News:Interventional radiology treatment for uterine fibroids: Safe, nonsurgical option 2Health News:Interventional radiology treatment for uterine fibroids: Safe, nonsurgical option 3Health News:Nile Therapeutics Reports 2009 Second Quarter Financial Results 2Health News:Nile Therapeutics Reports 2009 Second Quarter Financial Results 3Health News:Nile Therapeutics Reports 2009 Second Quarter Financial Results 4Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 2Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 3Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 4Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 5Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 6Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 7Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 8Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 9Health News:Birner Dental Management Services, Inc. Announces Earnings Per Share Up 33% for 2nd Quarter 2009 10Health News:Boozing Blunts Ability to Read Faces 2Health News:China Medicine Announces Second Quarter 2009 Results 2Health News:China Medicine Announces Second Quarter 2009 Results 3Health News:China Medicine Announces Second Quarter 2009 Results 4Health News:China Medicine Announces Second Quarter 2009 Results 5Health News:China Medicine Announces Second Quarter 2009 Results 6Health News:China Medicine Announces Second Quarter 2009 Results 7Health News:China Medicine Announces Second Quarter 2009 Results 8Health News:China Medicine Announces Second Quarter 2009 Results 9Health News:China Medicine Announces Second Quarter 2009 Results 10Health News:China Medicine Announces Second Quarter 2009 Results 11Health News:China Medicine Announces Second Quarter 2009 Results 12Health News:China Medicine Announces Second Quarter 2009 Results 13Health News:China Medicine Announces Second Quarter 2009 Results 14Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 2Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 3Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 4Health News:Interventional Radiology Treatment for Uterine Fibroids: Safe, Nonsurgical Option 5
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
... the best of both worlds, the ... is the latest addition to the ... bipolar cautery instruments for ophthalmic surgery. ... extrusion aspiration and backflush functionality in ...
...
...
Medicine Products: